E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 2/28/2006 in the Prospect News Biotech Daily.

Novavax, PacificGMP form alliance for pandemic flu vaccine production

By Elaine Rigoli

Tampa, Fla., Feb. 28 - Novavax, Inc. and PacificGMP, Inc. announced Tuesday that they have formed a strategic alliance to collaborate on the development of a commercial scale production process for Novavax's experimental pandemic influenza virus (avian flu) vaccine and other biological products.

Under the alliance, PacificGMP will assist Novavax in developing the capability of manufacturing large quantities of vaccine to accommodate the surge capacity that must be met in the event of a pandemic outbreak of influenza, according to a Novavax news release.

PacificGMP will use disposable bioprocessing technology to manufacture and produce Novavax's VLP avian flu vaccine. Use of this disposable bioprocessing technology will allow for faster production, with greatly reduced overall manufacturing costs.

This process also mitigates the possibility for cross-contamination in production, which should ultimately result in a VLP avian flu vaccine that will be available to the public in a much shorter time period.

"This agreement with PacificGMP brings another critical capability to Novavax in the development of our H5N1 avian influenza VLP vaccine, and puts Novavax a step closer to servicing the world at large in the event of a pandemic," said Dr. Rahul Singhvi, Novavax president and chief executive officer, in a statement.

Novavax said it is continuing with research and development on its avian flu vaccine and is currently conducting preclinical work before submitting an Investigational New Drug application to the Food and Drug Administration.

San Diego-based PacificGMP specializes in the development and manufacturing of biologics using disposable technology.

Novavax is focused on creating differentiated, value-added pharmaceutical and vaccine products and technologies. The company is based in Malvern, Pa.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.